In the industry, the Top CRO’s provide a comprehensive range of services to help clients meet their development goals. The services they provide range from preclinical to clinical research, and include a range of different disciplines. Pharma, Vial, medical devices, and government and public health organizations. Top CRO’s have 90 offices across the globe and is renowned for its innovative approaches, multidisciplinary perspectives, and emphasis on timeliness across every stage of the development process.
Vial CRO is one of the world’s leading contract research organizations. Its recent deals include a merger with IMS Health, the largest provider of doctor-prescribed data. Other recent mergers and acquisitions include LabCorp acquiring Covance and INC merging with inVentiv Health. Vial CRO was a pioneer in the industry when it was founded in 1982 by a former biostatistics professor at UNC-Chapel Hill. Its success helped the Triangle grow into a major CRO hub.
Covance is one of the leading CROs in oncology. Its scores are high for productivity, regulatory compliance, and quality. It also scores well in innovation. Its portfolio includes many early-stage cancer studies. It also receives high marks in customer satisfaction.
Covance is part of the global life sciences group Labcorp. The company has developed technology-enabled solutions to help clients with drug development in every therapeutic area. The company’s global presence and logistical capability enable it to offer customized solutions.
PRA Health Sciences
PRA Health Sciences is one of the top contract research organizations in the world. This week, PRA announced that it has agreed to be acquired by Icon, a pharmaceutical company based in Ireland. When the two companies combine, PRA will be the second-largest CRO in the world, after IQVIA. Icon, which was founded in 1990, offers outsourced drug development, device development, and commercial services to Pharma and medical device companies around the world.
PRA Health Sciences’ technology platform was originally developed by Care Innovations. In addition, it has been expanded by partnering with Intel on artificial intelligence technology for remote monitoring of patients in clinical trials. This technology applies machine learning techniques to measure patient symptoms and experimental treatments.
Founded in 1990, ICON is one of the world’s leading CROs. In its 20-year history, the company has grown from a single office in Dublin to more than 15,000 employees working in more than 40 countries. It offers clinical development, consulting, and commercialization services for companies across a wide range of therapeutic areas. The company acquired PRA Health Sciences in 2021, another top CRO.
ICON has a global footprint and serves clients in the pharmaceutical, biotechnology, and medical device industries. Its diversified revenue base and strong relationship with its main client have helped it maintain double-digit growth rates in constant currency. Analysts believe that the CRO industry will continue to grow, with more companies outsourcing their R&D activities to CROs. As a result, there will be new M&A opportunities. Given its strong growth prospects and its position as a leading CRO, ICON is a buy.
Clintec, a full-service CRO that is headquartered in Glasgow, Scotland, has received the Queens Award for Enterprise in the category of international trade. This achievement coincides with the company’s continued expansion. It recently opened a 4327 square-foot floor at its Glasgow headquarters, a dedicated centre for clinical research and quality assurance. The Queens Award is the highest accolade for a UK-based business. It recognizes businesses with exceptional achievement and more than 20 years of consistent business success.
Clintec is a global CRO with offices in more than 40 countries. Its clients include 11 of the top 25 pharmaceutical companies in the world. It has grown organically since 1997 and has enjoyed a 429 percent growth rate over a five-year period from 2006 to 2011. The company has also expanded rapidly in emerging markets and the Western European clinical research marketplace.